Lexaria Bioscience Corp. (NASDAQ:LEXX) | WebDisclosure

Basculer en Français

10936	Companies
238806	Keywords
167668	Articles
128366	Press releases

Headlines Articles Press releases Lexaria Bioscience Corp.

Home
Companies
Lexaria Bioscience Corp.

BRIEF

published on 12/23/2025 at 15:34, 8 months 12 days ago

Lexaria's Phase 1b Study Achieves Primary Endpoint

Drug Delivery Innovation Phase 1b Study Lexaria Bioscience DehydraTECH-semaglutide Side Effect Reduction
BRIEF

published on 12/23/2025 at 15:34, 8 months 12 days ago

L'étude de phase 1b de Lexaria atteint son critère d'évaluation principal

Innovation En Matière D'administration De Médicaments Étude De Phase 1b Lexaria Bioscience DehydraTECH-semaglutide Réduction Des Effets Secondaires
PRESS RELEASE

published on 12/23/2025 at 15:29, 8 months 12 days ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
Lexaria Bioscience Corp. announces DehydraTECH-semaglutide shows significant reduction in gastrointestinal side effects compared to Rybelsus®, with recent financings enabling new 2026 development opportunities

Financings DehydraTECH-semaglutide Lexaria Bioscience Corp. Rybelsus Gastrointestinal Side Effects
PRESS RELEASE

published on 09/21/2023 at 15:10, 2 years 11 months ago

Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD

Accesswire

Published on 09/05/2026 at 04:05, 2 hours 11 minutes ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 6 hours 46 minutes ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 7 hours 16 minutes ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 7 hours 46 minutes ago

Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 15 hours 46 minutes ago

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/04/2026 at 22:10, 8 hours 6 minutes ago

Quantinuum to Participate in the Bernstein 23rd Annual Pan-European Strategic Decisions Conference
Published on 09/04/2026 at 19:20, 10 hours 56 minutes ago

Dahua Technology Showcases Integrated Smart Living and Innovations at IFA Berlin 2026
Published on 09/04/2026 at 19:00, 11 hours 16 minutes ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
Published on 09/04/2026 at 18:55, 11 hours 21 minutes ago

Holding(s) in Company
Published on 09/04/2026 at 18:50, 11 hours 26 minutes ago

A&S Resources secures railway funding of USD$6 Billion to unlock $2.5 trillion iron ore asset

Les Echos

Published on 09/04/2026 at 18:57, 11 hours 19 minutes ago

Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 18:57, 11 hours 19 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 1er au 4 septembre 2026
Published on 09/04/2026 at 18:15, 12 hours 1 minute ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/04/2026 at 18:15, 12 hours 1 minute ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/04/2026 at 18:15, 12 hours 1 minute ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES AOÛT 2026

View all LES ECHOS COMFI WIRE